Large-scale production of recombinant adeno-associated virus (rAAV)

Shengwu Gongcheng Xuebao/Chinese Journal of Biotechnology

Volumn 25, Issue 11, 2009, Pages 1608-1613

  Wang, Feng ^a,b   Diao, Yong ^a,b   Xiao, Weidong ^a,b   Xu, Ruian ^a,b  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b HUAQIAO UNIVERSITY   (China)

Author keywords

Biotechnology; Cell; Human; Insect; Packaging; Recombinant adeno associated; Scale production

Indexed keywords

RECOMBINANT PROTEIN;

ADENO ASSOCIATED VIRUS; ANIMAL; BIOSYNTHESIS; BIOTECHNOLOGY; CYTOLOGY; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; INSECT; METABOLISM; METHODOLOGY; PHYSIOLOGY; REVIEW; VIRUS ASSEMBLY;

ANIMALS; BIOTECHNOLOGY; DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; HUMANS; INSECTS; RECOMBINANT PROTEINS; VIRUS ASSEMBLY;

ADENO-ASSOCIATED VIRUS; HEXAPODA; PARVOVIRUS;

EID: 77954773216     PISSN: 10003061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Xu RA, Chen L, Xiao WD. Molecular Gene Medicine. Beijing: Peking University Press and Peking University Medical Press, 2008: 2-40, 68-90.
2. Xu R, Sun X, Tse LY, et al. Long-term expression of angiostatin suppresses metastatic liver cancer in mice. Hepatology, 2003, 37(6): 1451-1460.
3. Shi J, Zheng D, Liu Y, et al. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res, 2005, 65(5): 1687-1692.
4. Eberling JL, Jagust WJ, Christine CW, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. hAADC. Neurology, 2008, 70(21): 1980-1983.
5. Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocularsubretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther, 2008, 19(10): 979-990.
6. Urabe M, Ding C, Kotin RM, et al. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther, 2002, 13(16): 1935-1943.
7. Muzyczka N. Use of adeno-associated virus as a general transduction, vector for mammalian cells. Curr Top Microbiol Immunol, 1992, 158: 97-129.
8. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol, 1998, 72(3): 2224-2232.
9. Xu R, Janson CG, Mastakov M, et al. Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes. Gene Ther, 2001, 8(17): 1323-1332.
10. During MJ, Xu R, Young D, et al. Peroral gene therapy of lactose intolerance using an adeno-associated virus vector. Nat Med, 1998, 4(10): 1131-1135.
11. Diao Y, Xu RA. Protocols of Cellular and Molecular Biotechnology. Beijing: Chemical Industry Press, 2008: 313-316.
12. Matsushita T, Okada T, Inaba T, et al. The adenovirus E1A and E1B19K genes provide a helper function for transfection-based adeno-associated virus vector production. J Gen Virol, 2004, 85(8): 2209-2214.
13. Reed SE, Staley EM, Mayginnes JP, et al. Transfection of mammalian cells using linear polyethylenimine is a simple and effective means of producing recombinant adeno-associated virus vectors. J Virol Methods, 2006, 138(1/2): 85-98.
14. Yang Q, Chen F, Trempe JP. Characterization of cell lines that inducibly express the adeno-associated virus Rep proteins. J Virol, 1994, 68(8): 4847-4856.
15. Vincent KA, Moore GE, Haiwood NL. Replication and packaging of HIV envelope genes in a novel adeno-associated virus vector system. Vaccine 90, Cold Spring Harbor Laboratory Press, 1990: 353-359.
16. Kenji T, Yukihiko H, Takashi S. A new strategy for large-scale preparation of high-titer recombinant adeno-associated virus vectors by using packaging cell lines and sulfonated cellulose column chromatography. Hum Gene Ther, 1996, 7(4): 507-513.
17. Clark KR, Voulgaropoulou F, Fraley DM. Cell lines for the production of recombinant adeno-associated virus. Hum Gene Ther, 1995, 6(10): 1329-1341.
18. Chadeuf G, Favre D, Tessier J, et al. Efficient recombinant adeno-associated virus production by a stable rep-cap Hela cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome. J Gene Med, 2000, 2(4): 260-268.
19. Michael S, Sandra A, Robert MK. Adeno-associated virus type 2 Rep78 induces apoptosis through caspase activation independently of p53. J Virol, 2000, 74(20): 9441-9450.
20. Qiao C, Li J, Skold A, et al. Feasibility of generating adeno-associated virus packaging cell lines containing inducible adenovirus helper genes. J Virol, 2002, 76(4): 1904-1913.
21. Qiao C, Wang B, Zhu X, et al. A novel gene expression control system and its use in stable, high-titer 293 cell-based adeno-associated virus packaging cell lines. J Virol, 2002, 76(24): 13015-13027.
22. Cecchini S, Negrete A, Kotin RM. Toward exascale production of recombinant adeno-associated virus for gene transfer applications. Gene Ther, 2008, 15(11): 823-830.
23. Alejandro N, Robert MK. Production of recombinant adeno-associated vectors using two bioreactor configurations at different scales. J Virol Methods, 2007, 145(2): 155-161.
24. Grieger JC, Samulski RJ. Adeno-associated virus as a gene therapy vector: development, production and clinical applications. Adv Biochem Eng Biotechnol, 2005, 99: 119-145.
25. Meghrous J, Aucoin MG, Jacob D, et al. Production of recombinant adeno-associated viral vectors using a baculovirus/insect cell suspension culture system: from shake flasks to a 20-L bioreactor. Biotechnol Prog, 2005, 21(1): 154-160.
26. Gilbert PA, Garnier A, Jacob D, et al. Online measurement of green fluorescent protein (GFP) fluorescence for the monitoring of recombinant adenovirus production. Biotechnol Lett, 2000, 22: 561-568.
27. Negrete A, Yang LC, Mendez AF, et al. Economized large-scale production of high yield of rAAV for gene therapy applications exploiting baculovirus expression system. J Gene Med, 2007, 9(11): 938-948.
28. Negrete A, Esteban G, Kotin RM. Process optimization of large-scale production of recombinant adeno-associated vectors using dielectric spectroscopy. Appl Microbiol Biotechnol, 2007, 76(4): 761-772.
29. Zaiss AK, Muruve DA. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther, 2008, 15(11): 808-816.
30. Farris KD, Pintel D. Improved splicing of the AAV capsid protein-supplying pre-mRNAs leads to increased rAAV vector production. Hum Gene Ther, 2008, 19(12): 1421-1427.
31. Wang J, Xie J, Lu H, et al. Existence of transient functional double-stranded DNA intermediates during recombinant AAV transduction. Proc Natl Acad Sci USA, 2007, 104(32): 13104-13109.
32. During MJ, Symes CW, Lawlor PA, et al. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science, 2000, 287(5457): 1453-1460.
33. Ma H, Liu Y, Liu S, et al. Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular. Hepatology, 2005, 42(6): 1355-1363.
34. O'Riordan CR, Lachapelle AL, Vincent KA, et al. Scaleable chromatographic purification process for recombinant adeno-associated virus (rAAV). J Gene Med, 2000, 2(6): 444-454.
35. Davidoff AM, Ng CY, Sleep S, et al. Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock. J Virol Methods, 2004, 121(2): 209-215.
36. Kaludov N, Handelman B, Chiorini JA. Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography. Hum Gene Ther, 2002, 13(10): 1235-1243.
37. Lu H, Qu G, Xu RA, et al. Systemic elimination of de novo capsid protein synthesis from replication competent AAV contamination. Mol Ther, 2009 (in press).